eli lilly retatrutide clinical trials gave mysterious access to weight loss drug to 79-year-old patient lilly retatrutide trial The drug

A person who loses 15kg total, with 10kg from visceral and subcutaneous fat and 5kg from lean tissue, ends up with a dramatically healthier metabolic profile than someone who loses the same amount but from less targeted locations

For many patients, this combination acts as the bridge that allows them to cross the finish line into 100% full, sustained clinical remission

A lifetime risk model asks a better question

Patients might experience nausea, vomiting and even diarrhea

In many cases, employer-sponsored health plans exclude weight-loss medications altogether, even when obesity-related conditions significantly impact overall health outcomes